XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Update

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) was the target of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 36,172 shares, a growth of 286.4% from the June 30th total of 9,362 shares. Based on an average daily trading volume, of 57,229 shares, the short-interest ratio is presently 0.6 days. Currently, 2.3% of the shares of the company are sold short.

XTL Biopharmaceuticals Trading Down 4.3%

Shares of NASDAQ:XTLB traded down $0.12 during trading on Monday, hitting $2.81. 1,287 shares of the stock were exchanged, compared to its average volume of 950,431. The company has a market cap of $6.19 million, a PE ratio of -4.40 and a beta of 1.45. XTL Biopharmaceuticals has a 12-month low of $2.01 and a 12-month high of $10.28. The company has a fifty day moving average price of $2.59 and a two-hundred day moving average price of $2.87.

Get XTL Biopharmaceuticals alerts:

XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of ($0.26) million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings raised XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

View Our Latest Stock Report on XTLB

XTL Biopharmaceuticals Company Profile

(Get Free Report)

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

See Also

• Five stocks we like better than XTL Biopharmaceuticals
• AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
• Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
• Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
• Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight

Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.